false 0001604950 0001604950 2024-05-16 2024-05-16

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 16, 2024

 

 

scPharmaceuticals Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-38293   46-5184075
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

 

25 Mall Road, Suite 203

Burlington, Massachusetts

  01803
(Address of principal executive offices)   (Zip Code)

(617) 517-0730

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

Common stock, par value $0.0001 per share   SCPH   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


Item 8.01. Other Events.

On May 16, 2024, scPharmaceuticals Inc. announced that, from launch through March 31, 2024, there have been approximately 47,000 total FUROSCIX doses written by around 2,200 unique prescribers and, of these, approximately 24,000 FUROSCIX doses had been filled. During the first quarter of 2024, there were approximately 17,400 doses written, of which approximately 8,100 doses were filled and 6,800 doses were payer cleared or pending.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    SCPHARMACEUTICALS INC.
Date: May 16, 2024     By:  

/s/ John H. Tucker

    Name:   John H. Tucker
    Title:   President and Chief Executive Officer
v3.24.1.1.u2
Document and Entity Information
May 16, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001604950
Document Type 8-K
Document Period End Date May 16, 2024
Entity Registrant Name scPharmaceuticals Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-38293
Entity Tax Identification Number 46-5184075
Entity Address, Address Line One 25 Mall Road
Entity Address, Address Line Two Suite 203
Entity Address, City or Town Burlington
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01803
City Area Code (617)
Local Phone Number 517-0730
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common stock, par value $0.0001 per share
Trading Symbol SCPH
Security Exchange Name NASDAQ
Entity Emerging Growth Company false

scPharmaceuticals (NASDAQ:SCPH)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more scPharmaceuticals Charts.
scPharmaceuticals (NASDAQ:SCPH)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more scPharmaceuticals Charts.